U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07697989) titled 'Pluvicto Real-world Investigation in Survival in Metastatic CRPC' on June 22.
Brief Summary: This study aims to evaluate the various aspects of treatment effectiveness of [177Lu]Lu-PSMA-617 (Pluvicto) in mCRPC patients in both pre- and post-taxane settings. The study will be conducted using real-world data sources from the United States (US) and Germany.
Study Start Date: June 30
Study Type: OBSERVATIONAL
Condition:
Prostatic Neoplasms, Castration-Resistant
Neoplasm Metastasis
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Published by HT Digital Content Services with permission from Health Daily Dig...